EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NASCarD (Nanopore Adaptive Sampling with Carrier DNA): A Rapid, PCR-Free Method for SARS-CoV-2 Whole-Genome Sequencing in Clinical Samples

Miguel A Terrazos Miani, Loïc Borcard, Sonja Gempeler, Christian Baumann, Pascal Bittel, Stephen L Leib, Stefan Neuenschwander, Alban Ramette iD

Pathogens · 2024

DOI: 10.3390/pathogens13010061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Miguel A Terrazos Miani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 25, 3001 Bern, Switzerland. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Whole Genome Sequencing, Genome, Viral. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Multidisciplinary Center for Infectious Diseases, Bern, Switzerland, Swiss National Science Foundation—Bridge Discovery.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whole-genome sequencing (WGS) represents the main technology for SARS-CoV-2 lineage characterization in diagnostic laboratories worldwide. The rapid, near-full-length sequencing of the viral genome is commonly enabled by high-throughput sequencing of PCR amplicons derived from cDNA molecules. Here, we present a new approach called NASCarD (Nanopore Adaptive Sampling with Carrier DNA), which allows a low amount of nucleic acids to be sequenced while selectively enriching for sequences of interest, hence limiting the production of non-target sequences. Using COVID-19 positive samples available during the omicron wave, we demonstrate how the method may lead to >99% genome completeness of the SARS-CoV-2 genome sequences within 7 h of sequencing at a competitive cost. The new approach may have applications beyond SARS-CoV-2 sequencing for other DNA or RNA pathogens in clinical samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Whole Genome SequencingGenome, ViralHumansHigh-Throughput Nucleotide SequencingRNA, Viral

Stichwörter der Autor:innen

SARS-CoV-2beta coronavirusesgenomicsnanopore sequencingnext-generation sequencingwhole-genome sequencing

Substanzen

RNA, Viral

Autor:innen und Institutionen

  • Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 25, 3001 Bern, Switzerland.

ORCID-Profile: Alban Ramette

Förderung

  • Multidisciplinary Center for Infectious Diseases, Bern, Switzerland
  • Swiss National Science Foundation—Bridge Discovery

Zitieren

APA

Terrazos Miani, M. A., Borcard, L., Gempeler, S., Baumann, C., Bittel, P., Leib, S. L., Neuenschwander, S., & Ramette, A. (2024). NASCarD (Nanopore Adaptive Sampling with Carrier DNA): A Rapid, PCR-Free Method for SARS-CoV-2 Whole-Genome Sequencing in Clinical Samples. Pathogens. https://doi.org/10.3390/pathogens13010061

Vancouver

Terrazos Miani MA, Borcard L, Gempeler S, Baumann C, Bittel P, Leib SL, et al. NASCarD (Nanopore Adaptive Sampling with Carrier DNA): A Rapid, PCR-Free Method for SARS-CoV-2 Whole-Genome Sequencing in Clinical Samples. Pathogens. 2024. doi:10.3390/pathogens13010061

BibTeX
@article{TerrazosMiani2024,
  author = {Terrazos Miani, Miguel A and Borcard, Loïc and Gempeler, Sonja and Baumann, Christian and Bittel, Pascal and Leib, Stephen L and Neuenschwander, Stefan and Ramette, Alban},
  title = {NASCarD (Nanopore Adaptive Sampling with Carrier DNA): A Rapid, PCR-Free Method for SARS-CoV-2 Whole-Genome Sequencing in Clinical Samples},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13010061}
}
Kostenlos starten →